Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Outcome Disparities in Caucasian and Non-Caucasian Patients With Myeloproliferative Neoplasms.

Clinical lymphoma, myeloma & leukemia - 1 Jun 2016

Khan Irum, Shergill Ardaman, Saraf Santosh L, Chen Yi-Fan, Patel Pritesh R, Quigley John G, Peace David, Gordeuk Victor R, Hoffman Ronald, Rondelli Damiano

Abstract excerpt

BACKGROUND: The Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are characterized by an increased risk of thrombotic and hemorrhagic complications. Large retrospective studies have demonstrated racial disparities in MPN outcomes and attributed this to differences in access to health care. Utilizing a single institution experience, we report outcomes in patients with polycythemia vera (PV),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ethnicity
Share to Illinois

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kaplan-Meier Estimate

Share to Mutation

Share to Myeloproliferative Disorders

Share to Outcome Assessment, Health Care

Share to White People

Source

Identifiers

PMID: 27052852
DOI: 10.1016/j.clml.2016.02.036

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcome Disparities in Caucasian and Non-Caucasian Patients With Myeloproliferative Neoplasms.PMID 27052852Read ↗

Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.Semantic proximity Read ↗

Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study.Semantic proximity Read ↗

Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger.Semantic proximity Read ↗

Topics of Interest in Women With Myeloproliferative Neoplasms.Semantic proximity Read ↗

Incidence rates and risk factors for vascular events in patients with essential thrombocythemia: a multicenter study from Korea.Semantic proximity Read ↗

Prognostic risk model for patients with high-risk polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Race-Related Differences in Thrombogenicity: An Explanation for Disparities in COVID-19 Outcomes?Semantic proximity Read ↗

Cerebrovascular risk factors are the predictive factor for ischemic cerebrovascular diseases in patients with Philadelphia chromosome (Ph)–negative myeloproliferative neoplasms: a case control studySemantic proximity Read ↗

Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia veraSemantic proximity Read ↗

Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real-world data from the Swedish MPN Registry.Semantic proximity Read ↗

Risk factors for ischemic stroke in patients with Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms.Semantic proximity Read ↗

Dysregulation of HIF-1α-regulated and thromboinflammatory genes may contribute to thrombotic risk in patients with BCR::ABL1-negative myeloproliferative neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.